Build your base

Alienum phaedrum torquatos nec eu, vis detraxit periculis ex, nihil expetendis in mei. Mei an pericula euripidis, hinc partem ei est.
Back to top

Gregory Reaman, MD

New Horizon / Gregory Reaman, MD

Gregory Reaman, MD

Associate Director for Oncology Sciences at Center for Drug Evaluation and Research, US FDA


Gregory Reaman is the Associate Director for Pediatric Oncology in the FDA’s Oncology Center of Excellence, Office of the Commissioner and Associate Director for Pediatrics in the Office of Oncologic Diseases, CDER. He is the Executive Director emeritus of the Center for Cancer and Blood Disorders and senior attending physician at Children’s National, Washington, D.C.. He has held numerous academic and clinical research leadership positions. He was the Inaugural Chair of the Children’s Oncology Group and previously served as the Associate Chair for New Agent Studies and Vice Chair for Scientific Affairs of the Children’s Cancer Group. He served on the national Board of Directors of the American Cancer Society and chaired its Task Force on Cancer in Children and on the Board of Directors of the American Society of Clinical Oncology and was a member of the Board of Directors of the International Society of Pediatric Oncology. He was the first pediatrician member of the FDA’s Oncologic Drugs Advisory Committee and the first chair of its Pediatric Subcommittee. He is a Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences. His research interests are in the immunobiology and therapy of acute leukemia and the development of new cancer therapeutics for children. He has authored more than 350 peer-reviewed publications.


Oct 28th 10:30 AM ET Panelist Session 2 – Reaching Agreement with Regulators on Global Approach to Pediatric Drug Development